Metastatic squamous cell carcinoma of the cervix: complete response under maintenance strategy with bevacizumab

Cervical carcinoma is a common cancer. Metastatic disease will develop in 15% to 61% percent women, usually within the first two years of completing treatment. We present a case of a 56-year-old patient with a Stage IIIB carcinoma of the cervix, treated with chemoradiation, brachytherapy and surgery. Nine months after completion of primary treatment, she presented with latero-aortic metastatic adenomegalies. She received six courses of chemotherapy carboplatin+paclitaxel+bevacizumab, followed by maintenance by bevacizumab. After ten months of bevacizumab and three years after the diagnosis, the patient is alive, without further evidence of disease.

Cervical cancer; Cervix; Maintenance strategy; Bevacizumab.

[1] Siegel R., Ma J., Zou Z., Jemal A.: “Cancer statistics, 2014”. CA Cancer J. Clin., 2014, 64, 9.

[2] Thigpen T., Shingleton H., Homesley H., Lagasse L., Blessing J.: “Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of cervix: a phase II study of the Gynecologic Oncology Group”. Cancer, 1981, 48, 899.

[3] Wright J.D., Viviano D., Powel M.A., Gibb R.K., Mutch D.G., Grigsby P.W., Rader J.S.: “Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer”. Gynecol. Oncol., 2006, 103, 489.